Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

Ferretti Group Pre-IPO: Peer Comp and Valuation

Ferretti Group Pre-IPO: Might Disappoint Again

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

<ul>
<li>Ferretti raised HKD 1,771million (USD 226m) from its global offering and will list on the Hong Kong Stock Exchange on Thursday, Mar 31st.</li>
<li>In our previous note, we looked at the company's key product segments, operating metrics, financials, and industry. We also compared the company with a close peer.</li>
<li>In this note, we provide an update before trading debut.</li>
</ul>


Ferretti raised HKD 1,771million (USD 226m) from its global offering and will list on the Hong Kong Stock Exchange on Thursday, Mar 31st.
In our previous note, we looked at the company's key product segments, operating metrics, financials, and industry. We also compared the company with a close peer.
In this note, we provide an update before trading debut.


Ferretti IPO Trading: Weak Demand and High Share Concentration

Ferretti SpA

Ferretti IPO Trading: Weak Demand and High Share Concentration